Replies to post #1672 on Interpace Biosciences Inc. (IDXG)

[beavissolid]

it's toxic financing at it's finest. This company doesn't have money, the company is baiting investors on...what funds are going to buy their offering at 4.69 when the PPS currently is 4.30??? IDXG didn't even close the last offering @ 6 whatever it was.
the chart is bearish, the toxic financing is bearish, the management is shaddy. They bait people into buying their stock 100%. Plus, now you have government risk with Trump in office.

[Renegades17]

Keep in mind that they can't claim to have cured the minimum equity requirement until they file financials for the first quarter. The first offering in January, which would have cured the equity deficiency, didn't close until after December quarter end. This is why they can only say that they will file a plan with the exchange showing them that they have cured the deficiency through that offering. The exchange will see that the pro forma equity account is well above the minimum threshold and I assume that the company will provide an estimate of first quarter profit/loss that won't alter the claim that the deficiency has been cured.

I called RedChip late on Friday, but hope to speak to them today. These outsourced IR firms are generally useless for the reason you stated. I think a simple PR that states the current cash balance and some idea on the cash requirements for the business would be very helpful. I will also convey that's poor form to do an offering immediately after releasing positive news.

With all that said, I do see a lot of upside in the stock and very little downside. I think the existing tests and the US market can support a $20-$30 stock price with current insurers. If they add more insurers and expand internationally, it could multiples higher (over time obviously).